These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26964739)

  • 21. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
    Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T
    Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
    Kudoh A; Oishi T; Itamochi H; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
    Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
    Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
    Ricci F; Guffanti F; Damia G; Broggini M
    Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
    Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
    Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
    Shah DK; Veith J; Bernacki RJ; Balthasar JP
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):951-8. PubMed ID: 21305289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer.
    García-Vázquez R; Gallardo Rincón D; Ruiz-García E; Meneses García A; Hernández De La Cruz ON; Astudillo-De La Vega H; Isla-Ortiz D; Marchat LA; Salinas-Vera YM; Carlos-Reyes Á; López-González S; Ramos-Payan R; López-Camarillo C
    Oncol Rep; 2018 Jun; 39(6):3086-3094. PubMed ID: 29658612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
    Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro].
    Zhang SL; Jiang T; Lin B; Zhao CQ; Meng LR
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):482-5. PubMed ID: 15347474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
    Guo Y; Nemeth J; O'Brien C; Susa M; Liu X; Zhang Z; Choy E; Mankin H; Hornicek F; Duan Z
    Clin Cancer Res; 2010 Dec; 16(23):5759-69. PubMed ID: 20699329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
    He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
    Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
    Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
    Cheraghchi-Bashi A; Parker CA; Curry E; Salazar JF; Gungor H; Saleem A; Cunnea P; Rama N; Salinas C; Mills GB; Morris SR; Kumar R; Gabra H; Stronach EA
    Oncotarget; 2015 Dec; 6(39):41736-49. PubMed ID: 26497682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice.
    Tuppurainen L; Sallinen H; Karvonen A; Valkonen E; Laakso H; Liimatainen T; Hytönen E; Hämäläinen K; Kosma VM; Anttila M; Ylä-Herttuala S
    Int J Gynecol Cancer; 2017 Jun; 27(5):879-886. PubMed ID: 28498260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Curcumin induces autophagy, inhibits proliferation and invasion by downregulating AKT/mTOR signaling pathway in human melanoma cells.
    Zhao G; Han X; Zheng S; Li Z; Sha Y; Ni J; Sun Z; Qiao S; Song Z
    Oncol Rep; 2016 Feb; 35(2):1065-74. PubMed ID: 26573768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.